Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD)

• Status: Completed
• Trial end date: 2006-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Atomoxetine versus placebo in Children with Attention-Deficit/Hyperactivity Disorder (ADHD)

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Atomoxetine Hydrochloride

Criteria

Inclusion Criteria:

• Patients are diagnosed with ADHD

• Patients must be able to swallow capsules

• Patients must be of normal intelligence

Exclusion Criteria:

• Patients who weigh less than 15 kg or more than 75 kg

• Patients with organic brain disease (for example, dementia or traumatic brain injury residual)